Lv3
252 积分 2024-03-29 加入
Emerging biomarkers in breast cancer: translational and multi-omics perspectives in precision oncology
1个月前
已完结
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
1个月前
已完结
Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer
1个月前
已完结
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights
1个月前
已完结
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
1个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1个月前
已完结
MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer
1个月前
已完结
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
1个月前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
1个月前
已完结
皖公网安备34019202002308
